Is very high LDL safe in a lean, metabolically healthy person on a low-carb diet?
The lean-mass-hyper-responder (LMHR) phenotype - very high LDL with high HDL and low triglycerides on carbohydrate restriction - is low cardiovascular risk despite the high LDL/ApoB.
Some lean, fit, low-carb dieters see their LDL soar while keeping high HDL and low triglycerides - the opposite of the usual high-risk pattern. The open question is whether this particular very-high-LDL state is dangerous. There is not yet long-term outcome data either way, so this is the most genuinely unsettled claim on the site.
Evidence balance
Mainstream steelman
Causal-LDL proponents argue the phenotype does not earn an exemption. ApoB-bearing particles are believed to drive atherosclerosis regardless of why they are elevated, and LMHRs can have ApoB well into high-risk ranges. Atherosclerosis develops over decades, so a single cross-sectional snapshot of a small, self-selected cohort cannot establish safety - and the attempted one-year longitudinal follow-up was retracted over methodology concerns, so there is currently no reliable longitudinal plaque data to lean on either way. Favourable metabolic markers may slow atherogenesis but do not confer immunity to it.
Skeptic steelman
Proponents argue this phenotype breaks the simple LDL model. These individuals are insulin-sensitive with an excellent triglyceride/HDL ratio - a profile that tracks with large buoyant LDL and low risk - and in the first cross-sectional imaging study, plaque burden did not correlate with their very high LDL. Mechanistically (the Lipid Energy Model) the LDL elevation reflects fat-based fuel trafficking, not the atherogenic dyslipidemia of metabolic disease. They argue judging them by particle count alone ignores the context that determines whether particles become atherogenic.
Bottom line
Low confidenceThis is genuinely unresolved. The metabolic profile is favourable and the cross-sectional baseline plaque data were reassuring, but that is a snapshot, there is no hard-outcome data, and the one-year longitudinal follow-up was retracted - so the most-cited progression evidence is currently off the table. Honest verdict: not demonstrated to be dangerous, and not demonstrated to be safe - the high LDL/ApoB should not simply be dismissed.
This is a clearly-labelled editorial judgment, not a fact. It is written to survive its own skeptic steelman above.
What would change this conclusion
Multi-year outcome or robust plaque-progression data in LMHRs versus matched controls: clear progression tied to LDL/ApoB would refute the low-risk claim; durable absence of progression and events would support it.
The evidence (3)
Strongest evidence first. Each card traces to a study and a verbatim quote with a locator.
- ChallengesLow tierComposite clinical outcome
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
European Heart Journal, 2017 - Guideline Or Consensus
The mainstream causal framework implies that a phenotype with sustained very high LDL/ApoB carries elevated risk regardless of why the LDL is high, which challenges the low-risk claim. It is indirect: the consensus explicitly synthesises general populations and does not examine metabolically-healthy high-LDL individuals.
“Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.”
Applicability: General populations; LMHR phenotype not examined - this is an extrapolation of the framework.
Tier adjusted: Downgraded from the source tier (high) because the consensus does not address the LMHR phenotype, so it is indirect for this specific claim.
- Applies a general conclusion to a phenotype the statement did not study.
- ChallengesLow tierCoronary event
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis
Journal of the American College of Cardiology, 2012 - Mendelian Randomization
If lifelong higher LDL/particle exposure causally raises coronary risk, then a phenotype with sustained very high LDL/ApoB should not be assumed safe on the basis of favourable metabolic markers alone. This challenges the low-risk claim in principle, but is indirect: the genetic evidence says nothing specific about the LMHR phenotype, which may differ in particle quality or biology.
“Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.”
Applicability: No LMHR phenotype represented in MR cohorts; extrapolation, not direct evidence.
Tier adjusted: Downgraded from the source tier (high) because the Mendelian-randomization cohorts contain no LMHR individuals, making it indirect evidence for this specific phenotype.
- Cumulative-exposure logic applied to a phenotype the study did not examine.
- SupportsLow tierPlaque imaging (surrogate)
Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial
JACC: Advances, 2024 - Imaging Study
The most directly relevant evidence for the phenotype: in lean, metabolically healthy people with very high diet-induced LDL, baseline coronary plaque was no greater than matched lower-LDL controls, and LDL-C did not track plaque. It is only low tier because it is cross-sectional, small, and uses plaque (a surrogate) rather than events - it is suggestive, not dispositive.
“Coronary plaque in metabolically healthy individuals with carbohydrate restriction-induced LDL-C ≥190 mg/dL on KETO for a mean of 4.7 years is not greater than a matched cohort with 149 mg/dL lower average LDL-C. There is no association between LDL-C and plaque burden in either cohort.”
Applicability: Directly the LMHR phenotype; cross-sectional baseline; surrogate endpoint; no events.
- The one-year longitudinal follow-up was retracted (methodology concerns), so longitudinal plaque-progression data are not currently available; this is a cross-sectional snapshot only.
- Small (n=80), self-selected; matched to an external control cohort.